GlassScriptPhysician profile
Alexander Fruchter
NPI 1740234160
$13,997.89
in general payments reported to CMS, 2019-2025
47 companies · $1,843 in 2025
The $1,843 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,622 · 2020: $1,621 · 2021: $2,572 · 2022: $2,611 · 2023: $1,950 · 2024: $1,779 · 2025: $1,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,284 · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,284.49 |
| Education | $287.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,998.56 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,648.09 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $1,116.76 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Regeneron Healthcare Solutions, INC. | $938.25 | 2020-2025 | Dupixent |
| Genzyme Corporation | $882.32 | 2021-2025 | |
| Novo Nordisk INC | $763.49 | 2019-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $699.35 | 2019-2025 | Jardiance, Synjardy, Glyxambi |
| Abbvie INC. | $557.29 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $502.31 | 2022-2025 | |
| Amgen INC. | $350.60 | 2019-2025 | Repatha, Otezla, Tezspire |
| Axsome Therapeutics, INC. | $334.16 | 2023-2025 | Sunosi, Auvelity |
| Janssen Pharmaceuticals, INC | $309.69 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $280.68 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $256.61 | 2019-2025 | |
| Exact Sciences Corporation | $251.58 | 2023-2025 | Cologuard Collection Kit |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Fruchter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.